Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: A single-center retrospective observational study in Tokyo, Japan

Nakamura, Shohei; Kanemasa, Yusuke; Atsuta, Yuya; Fujiwara, Sho; Tanaka, Masaru; Fukushima, Kazuaki; Kobayashi, Taiichiro; Shimoyama, Tatsu; Omuro, Yasushi; Sekiya, Noritaka; Imamura, Akifumi

doi:10.21203/rs.3.rs-39157/v1

Cited by 8 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, such laboratory parameters in addition to measurement of the peripheral oxygen saturation in consideration of comorbidities might be of help to identify COVID-19 patients at risk of having a severe disease course, which is in accordance with previously published reports [21,22].…”

Section: Original Articlesupporting

confidence: 89%

Clinical characterization of hospitalized COVID-19 patients during the second wave of pandemic in the district of Rohrbach, Upper Austria

Rosenberger

Pöschl

Geschev

et al. 2021

Wien Klin Wochenschr

View full text Add to dashboard Cite

During the peak of the second wave of the coronavirus disease 2019 (COVID-19) pandemic in November 2020, the district of Rohrbach, Upper Austria, was reported to have had the highest 7-day incidence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive cases worldwide. In this study, we present the clinical characteristics of COVID-19 cases during the second wave of the pandemic in patients admitted to the only primary care hospital in the district of Rohrbach between October 2020 and February 2021. In total, 260 patients were hospitalized with a mean age of 72 years and a mortality rate of 14.6% and 13 patients (5%) were transferred to the intensive care unit (ICU). Critically ill patients (22.7%) were of older age and often lived in retirement and nursing facilities as compared to mild or moderately ill patients. Patients with a severe disease course showed significantly longer hospitalization, a worse peripheral oxygen saturation on admission and significantly higher levels of C-reactive protein (CRP), procalcitonin (PCT), lactate dehydrogenase (LDH), troponin I and D-dimer as compared to mild or moderate COVID-19 cases. These laboratory parameters might help to identify COVID-19 patients with a se-

show abstract

Section: Original Articlesupporting

confidence: 89%

Clinical characterization of hospitalized COVID-19 patients during the second wave of pandemic in the district of Rohrbach, Upper Austria

Rosenberger

Pöschl

Geschev

et al. 2021

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…33,39,50,51,55,56 Gynecologic cancer had fewer Covid-19 associated death compared to other cancer according to 30 studies (OR 0.82, CI 0.71-0.94, p 0.006, I 2 0%) Figure 2 . 18-20,24-28,30,32,37,39-42,45,46,48,50,52-55,57,58,60 Covid-19 associated severity was not significant from 6 studies between gynecologic cancer and other cancer (OR 0.56, CI 0.30-1.03, p 0.06, I 2 0%) Fig. S4 .…”

Section: Resultsmentioning

confidence: 97%

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Winata

Simatupang

Polim

et al. 2022

Preprint

View full text Add to dashboard Cite

ObjectiveCancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer.MethodsSearches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557).ResultsWe accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, p 0.01), (OR 0.26, CI 0.10-0.67 p 0.005), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.51, CI 1.20-1.90, p 0.0004), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 3.06, CI 2.32-4.04, p <0.0001) respectively.ConclusionGynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.SynopsisThis is a systematic review and meta analysis study that presents pooled evidence of outcome among gynecologic cancer patients infected with the Covid-19 infection. We manage to gather 49 studies involving 1994 gynecologic cancer patients with Covid-19, 220967 non cancer patients with Covid-19, 4080990 cancer patients without Covid-19 and 28658 non gynecologic cancer patients with Covid-19 for analysis. Meta analysis shows reduction of Covid-19 death with gynecologic cancer patients vs overall other cancer, lung cancer, and hematologic cancer (OR 0.84, CI 0.72-0.97, p 0.02), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. On the contrary, increased risk of Covid-19 death occur to gynecologic cancer patients vs infected non cancer, non Covid cancer patients, and infected breast cancer patients (OR 3.06, CI 2.32-4.04, p <0.0001), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 1.51, CI 1.20-1.90, p 0.0004) respectively. Analysis from SARS-Cov-2 infection shows lower infection with gynecologic cancer patients vs hematologic cancer cohort (OR 0.71, CI 0.56-0.89, p 0.003). We hope the result of this meta analysis will be useful to providers practicing in cancer centers and tertiary cancer referral hospitals thus better practices and care services given to gynecologic cancer patients infected with / without the Covid-19 during the ongoing global pandemic can be achieved.To our knowledge this is the first systematic review and meta analysis which emphasizes on reporting the outcome of gynecologic cancer patients with the Covid-19 infection. We also found no publication bias across 49 studies we have gathered and used as meta analysis data.

show abstract

“…Some cases where patients who previously tested negative on PCR tested positive again after a certain period of time have been reported [ 8 – 10 ]. In an Italian study, 16.7% of patients who had recovered from COVID-19 tested positive again at least 2 weeks after their previous negative test (mean time elapsed since initial infection approximately 2 months) (0.11).…”

Section: Testingmentioning

confidence: 99%

Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan

et al. 2021

View full text Add to dashboard Cite

Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: A single-center retrospective observational study in Tokyo, Japan

Cited by 8 publications

References 26 publications

Clinical characterization of hospitalized COVID-19 patients during the second wave of pandemic in the district of Rohrbach, Upper Austria

Clinical characterization of hospitalized COVID-19 patients during the second wave of pandemic in the district of Rohrbach, Upper Austria

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan

Contact Info

Product

Resources

About